Publications by authors named "Jason Halladay"

Claim this Profile
G
GTP1 metabolic stability assessment: A study of the tau PET tracer [F]GTP1.
Jan Marik, Sharyl Rich, Gauri Deshmukh, Donglu Zhang, Jeff Tinianow, Jason Halladay

Nucl Med Biol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of an orally active benzoxaborole prodrug effective in the treatment of Chagas disease in non-human primates.
Angel M Padilla, Wei Wang, Tsutomu Akama, David S Carter, Eric Easom, Jason S Halladay

Nat Microbiol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case Study 9: Probe-Dependent Binding Explains Lack of CYP2C9 Inactivation by 1-Aminobenzotriazole (ABT).
Jasleen K Sodhi, Jason S Halladay

Methods Mol Biol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Improved Resistance Potential of a Cofactor-Independent InhA Inhibitor of Mycobacterium tuberculosis in the C3HeB/FeJ Mouse Model.
Gregory T Robertson, Victoria A Ektnitphong, Michael S Scherman, Matthew B McNeil, Devon Dennison, Jason Halladay

Antimicrob Agents Chemother· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Boron-Pleuromutilins as Anti- Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis.
Robert T Jacobs, Christopher S Lunde, Yvonne R Freund, Vincent Hernandez, Xianfeng Li, Jason Halladay

J Med Chem· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effects of Drug Metabolizing Enzyme Inhibitors on Hepatic Efflux and Uptake Transporters.
Jonathan Cheong, Jason S Halladay, Emile Plise, Jasleen K Sodhi, Laurent Salphati

Drug Metab Lett· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a cofactor-independent inhibitor of InhA.
Yi Xia, Yasheen Zhou, David S Carter, Matthew B McNeil, Wai Choi, Jason Halladay

Life Sci Alliance· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitory Effects of Trapping Agents of Sulfur Drug Reactive Intermediates against Major Human Cytochrome P450 Isoforms.
Jasleen K Sodhi, Erlie Marie Delarosa, Jason S Halladay, James P Driscoll, Teresa Mulder

Int J Mol Sci· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Mechanism of Decyanation of GDC-0425 by Cytochrome P450.
Ryan H Takahashi, Jason S Halladay, Michael Siu, Yuan Chen, Cornelis E C A Hop

Drug Metab Dispos· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Going Beyond Common Drug Metabolizing Enzymes: Case Studies of Biotransformation Involving Aldehyde Oxidase, γ-Glutamyl Transpeptidase, Cathepsin B, Flavin-Containing Monooxygenase, and ADP-Ribosyltransferase.
Peter W Fan, Donglu Zhang, Jason S Halladay, James P Driscoll, S Cyrus Khojasteh

Drug Metab Dispos· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
Ryan H Takahashi, Edna F Choo, Shuguang Ma, Susan Wong, Jason Halladay

Drug Metab Dispos· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834.
Jasleen K Sodhi, Susan Wong, Donald S Kirkpatrick, Lichuan Liu, S Cyrus Khojasteh, Jason S Halladay

Drug Metab Dispos· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitigation of Acetylcholine Esterase Activity in the 1,7-Diazacarbazole Series of Inhibitors of Checkpoint Kinase 1.
Lewis Gazzard, Karen Williams, Huifen Chen, Lorraine Axford, Elizabeth Blackwood, Jason Halladay

J Med Chem· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1.
Lewis Gazzard, Brent Appleton, Kerry Chapman, Huifen Chen, Kevin Clark, Jason Halladay

Bioorg Med Chem Lett· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1-Aminobenzotriazole coincubated with (S)-warfarin results in potent inactivation of CYP2C9.
Jasleen K Sodhi, Kevin A Ford, Sophie Mukadam, Susan Wong, Cornelis E C A Hop, Jason S Halladay

Drug Metab Dispos· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors.
Anthony A Estrada, Bryan K Chan, Charles Baker-Glenn, Alan Beresford, Daniel J Burdick, Jason Halladay

J Med Chem· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Learning and confirming with preclinical studies: modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist.
Harvey Wong, Stephen E Gould, Nageshwar Budha, Walter C Darbonne, Edward E Kadel, Jason S Halladay

Drug Metab Dispos· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On the maintenance of hepatocyte intracellular pH 7.0 in the in-vitro metabolic stability assay.
Leonid M Berezhkovskiy, Susan Wong, Jason S Halladay

J Pharmacokinet Pharmacodyn· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900.
Elizabeth Blackwood, Jennifer Epler, Ivana Yen, Michael Flagella, Tom O'Brien, Jason Halladay

Mol Cancer Ther· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An algorithm for evaluating potential tissue drug distribution in toxicology studies from readily available pharmacokinetic parameters.
Patrick Poulin, Donna M Dambach, Dylan H Hartley, Kevin Ford, Frank-Peter Theil, Jason Halladay

J Pharm Sci· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lead identification of novel and selective TYK2 inhibitors.
Jun Liang, Vickie Tsui, Anne Van Abbema, Liang Bao, Kathy Barrett, Jason Halladay

Eur J Med Chem· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors.
Jun Liang, Anne van Abbema, Mercedesz Balazs, Kathy Barrett, Leo Berezhkovsky, Jason Halladay

J Med Chem· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An 'all-inclusive' 96-well cytochrome P450 induction method: measuring enzyme activity, mRNA levels, protein levels, and cytotoxicity from one well using cryopreserved human hepatocytes.
Jason S Halladay, Susan Wong, S Cyrus Khojasteh, Susan Grepper

J Pharmacol Toxicol Methods· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative assessment of In Vitro-In Vivo extrapolation methods used for predicting hepatic metabolic clearance of drugs.
Patrick Poulin, Cornelis E C A Hop, Quynh Ho, Jason S Halladay, Sami Haddad

J Pharm Sci· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis